GRI.NASDAQGri Bio, INC

10-Q: GRI Bio Reports Q1 2025 Results, Cites Ongoing Clinical Trials and Funding Initiatives

Sentiment:

Quarterly Report

📋All filings for Gri Bio, INC
🔒Login to Follow

GRI Bio, Inc. announces its financial results for the first quarter of 2025, highlighting ongoing clinical trials for GRI-0621 and efforts to secure additional funding.

Capital raiseThe company intends to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements.On April 1, 2025, the Company entered into a securities purchase agreement (the April 2025 Purchase Agreement), pursuant to which the Company agreed to sell, in a public offering (the April 2025 Offering), (i) 202,000 shares (the April 2025 Shares) of Common Stock, (ii) 1,186,888 pre-funded warrants (the April 2025 Pre-Funded Warrants) exercisable for an aggregate of 1,186,888 shares of Common Stock, (iii) 1,388,888 Series E-1 common stock warrants (the Series E-1 Common Warrants) to purchase up to 1,388,888 shares of Common Stock, (iv) 1,388,888 Series E-2 common stock warrants (the Series E-2 Common Warrants) to purchase up to 1,388,888 shares of Common Stock, and (v) 1,388,888 Series E-3 common stock warrants (the Series E-3 Common Warrants, and collectively with the Series E-1 Warrants and the Series E-2 Warrants, the Series E Common Warrants) to purchase up to 1,388,888 shares of Common Stock, for gross proceeds of $5,000, before deducting offering expenses.
Worse than expectedThe company's net loss increased from $1.9 million in Q1 2024 to $3.0 million in Q1 2025.

Summary

  • GRI Bio, Inc., a clinical-stage biopharmaceutical company, reported its financial results for the quarter ended March 31, 2025.
  • The company is focused on developing therapies for inflammatory, fibrotic, and autoimmune disorders.
  • GRI Bio's lead product candidate, GRI-0621, is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF).
  • The company's product candidate portfolio also includes GRI-0803, which is being developed for the treatment of autoimmune disorders.
  • The company effected a reverse stock split of its Common Stock at a ratio of one-for-seventeen on February 21, 2025.
  • The company had cash of approximately $3.3 million as of March 31, 2025.
  • The company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements through the third quarter of 2025.
  • The company intends to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements.
  • The company incurred a net loss of $3.0 million for the three months ended March 31, 2025, compared to a net loss of $1.9 million for the three months ended March 31, 2024.
  • Research and development expenses were $1.6 million for the three months ended March 31, 2025, compared to $0.9 million for the three months ended March 31, 2024.
  • General and administrative expenses were $1.4 million for the three months ended March 31, 2025, compared to $1.0 million for the three months ended March 31, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company is making progress in its clinical trials and has secured additional funding, it is also facing increasing losses and has a limited cash runway. The need for additional financing creates uncertainty about its future prospects.

Positives

  • GRI Bio has a clear focus on developing therapies for serious diseases with unmet medical needs.
  • The company has advanced its lead product candidate, GRI-0621, into a Phase 2a biomarker study for IPF.
  • The company has a proprietary library of 500+ compounds, providing a pipeline for future development.
  • The company has successfully raised capital through multiple offerings, including the February 2024 and April 2025 offerings, and the ATM offering.
  • The company is actively managing its cash resources and has a plan to extend its runway through additional financing.

Negatives

  • The company has a history of operating losses and an accumulated deficit of $42.8 million as of March 31, 2025.
  • The company's existing cash is only expected to fund operations through the third quarter of 2025, requiring additional financing.
  • The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
  • The company's research and development expenses have increased, contributing to a larger net loss in Q1 2025 compared to Q1 2024.
  • The company has a material weakness in its internal control over financial reporting.

Risks

  • The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
  • If the company is unable to obtain additional financing, it may be forced to reduce or discontinue its operations.
  • The company's research and development efforts may not be successful, and its product candidates may not receive regulatory approval.
  • The company faces competition from other companies developing therapies for the same diseases.
  • The company's stock price may be volatile, and investors may lose money on their investment.

Future Outlook

Based on the company's current operating plan, existing cash and cash equivalents are expected to fund operating expenses and capital expenditure requirements through the third quarter of 2025; the company intends to raise additional capital through equity or debt financing.

Management Comments

  • The company's goal is to be an industry leader in developing therapies to treat serious diseases and to improve the lives of patients suffering from such diseases.

Industry Context

GRI Bio operates in the competitive biopharmaceutical industry, focusing on therapies for inflammatory, fibrotic, and autoimmune disorders. The company's lead product candidate, GRI-0621, targets IPF, a disease with limited treatment options and significant unmet medical needs. The company's focus on iNKT cell modulation represents a novel approach to treating these diseases.

Comparison to Industry Standards

  • GRI Bio's financial position and cash runway are relatively short compared to larger, more established biopharmaceutical companies.
  • Companies like Boehringer Ingelheim and Roche, which have approved therapies for IPF, have significantly greater resources and revenue streams.
  • GRI Bio's reliance on equity financing is common among smaller biotech firms, but it also carries the risk of dilution for existing shareholders.
  • The company's research and development expenses are relatively low compared to industry averages, reflecting its stage of development and focus on specific programs.

Stakeholder Impact

  • Shareholders face potential dilution from future equity offerings.
  • Employees' job security is dependent on the company's ability to secure additional funding.
  • Patients with IPF and autoimmune disorders may benefit from the company's development of new therapies.
  • Suppliers and creditors face the risk of delayed payments if the company experiences financial difficulties.

Next Steps

  • The company expects interim data from the Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF to be available in the second quarter of 2025.
  • The company expects topline results from this trial to be available in the third quarter of 2025.
  • The company intends to file an IND application with respect to a Phase 1a and 1b trial initially targeting SLE in 2025.
  • The company expects to continue to evaluate indications to select the best fit for further development of the GRI-0803 program.

Key Dates

DateDescription
May 2009GRI Bio, Inc. was incorporated in Delaware.
April 21, 2023David Baker, the Company's Former Chief Executive Officer, resignation date.
January 29, 2024The Company effected a reverse stock split of its Common Stock at a ratio of one-for-seven.
February 1, 2024The Company entered into a securities purchase agreement (the February 2024 Purchase Agreement).
June 17, 2024The Company effected a reverse stock split of its Common Stock at a ratio of one-for-thirteen.
June 26, 2024The Company entered into a securities purchase agreement (the June 2024 Purchase Agreement).
September 10, 2024The Company received a letter from the Listings Qualification Department (the Staff) of The Nasdaq Stock Market LLC, indicating that we no longer met the Minimum Bid Price Rule.
October 21, 2024The Company entered into letter agreements (the Repricing Letter Agreements) with certain holders (the Holders) of certain of its issued and outstanding common warrants to purchase shares of its Common Stock, offering these Holders the opportunity to exercise all of their common warrants for cash at a reduced exercise price.
February 11, 2025The stockholders of the Company approved a reverse stock split of our common stock, par value $0.0001 per share (Common Stock), within the range of not less than one-for-2 and not more than one-for-23.
February 21, 2025The Company effected a reverse stock split of its Common Stock at a ratio of one-for-seventeen.
February 24, 2025Shares of our Common Stock began trading on a post-split basis.
March 10, 2025The Company received a letter from the Staff indicating that we were once again in compliance with the Minimum Bid Price Rule.
March 14, 2025The Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (the SEC).
March 31, 2025End of the quarterly period for this report; cash of approximately $3,281.
April 1, 2025The Company entered into a securities purchase agreement (the April 2025 Purchase Agreement).
April 2, 2025The April 2025 Offering closed.
May 5, 2025The Company filed a prospectus supplement to its registration statement on Form S-3 (File No. 333-279348) to increase the amount of shares of Common Stock that the Company may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $1,671.
May 14, 2025As of May 14, 2025, 2,141,473 shares of the Registrants common stock were outstanding.
May 15, 2025Date of this report.

Keywords

GRI Bio, biopharmaceutical, clinical trials, GRI-0621, GRI-0803, idiopathic pulmonary fibrosis, autoimmune disorders, financing, reverse stock split, financial results

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.